Related Experiment Videos
[Protein- and peptide-derived radiopharmaceuticals]
1Department of Radiopharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University.
Kaku Igaku. the Japanese Journal of Nuclear Medicine
|October 1, 1996
Summary
Radiopharmaceuticals are crucial for medical imaging and therapy, but radioactivity in non-target tissues remains a challenge. New polypeptide designs facilitate rapid urinary excretion of radiometabolites, improving diagnostic accuracy and therapeutic efficacy.
Area of Science:
- Radiochemistry
- Protein Engineering
- Molecular Imaging
Context:
- Advancements in radiochemistry enable stable radiolabeling of proteins in vivo.
- Genetic and protein engineering yield proteins/peptides with improved immunogenicity and biodistribution.
- Radioactivity accumulation in non-target tissues hinders accurate diagnosis and effective therapy with radiopharmaceuticals.
Purpose:
- To address the challenge of radioactivity localization in non-target tissues for radiopharmaceuticals.
- To explore the role of radiometabolites from lysosomal proteolysis in non-target tissue radioactivity.
- To develop novel radiopharmaceutical designs for enhanced clearance and reduced off-target effects.
Summary:
- Recent studies highlight radiometabolites from lysosomal proteolysis as key contributors to non-target tissue radioactivity.
- Designing polypeptides that yield rapidly excreted radiometabolites after proteolysis can significantly reduce radioactivity in non-target tissues.
- This approach facilitates rapid elimination of radioactivity via urinary excretion.
Impact:
- Paves the way for a new generation of protein- and peptide-derived radiopharmaceuticals.
- Enhances the suitability of radiopharmaceuticals for diagnostic and therapeutic applications.
- Improves the safety and efficacy of molecular imaging and targeted radionuclide therapy.